Clinical Immuno-Oncology | Agenda Bookshop Skip to content
Selected Colleen Hoover Books at €9.99c | In-store & Online
Selected Colleen Hoover Books at €9.99c | In-store & Online
A01=John E. Niederhuber
Age Group_Uncategorized
Age Group_Uncategorized
Author_John E. Niederhuber
automatic-update
Category1=Non-Fiction
Category=MJCL
COP=United States
Delivery_Delivery within 10-20 working days
Language_English
PA=In stock
Price_€100 and above
PS=Active
softlaunch

Clinical Immuno-Oncology

English

By (author): John E. Niederhuber

Offering focused, practical, and up-to-date content on immunotherapies used to treat a wide variety of cancer types, Clinical Immuno-Oncology covers the basic cellular and molecular mechanisms involved in cancer initiation and progression. The text reviews the development of tumor specific antigens and the challenges of developing cancer immunotherapies. Every effort is made to relate the fundamental aspects of host immunity to the efficacy of current immunotherapies and how they work in conjunction with the immune system to combat cancer. This foundational resource explains the basics of cancer immunotherapy, discusses best practices, and provides recommendations from experienced clinicians in the field. Dr. John E. Niederhuber and a team of expert contributing authors provide clinically focused information essential for integrating these new therapies into practice-making this an ideal resource for fellows, practitioners, and other cancer team members in medical oncology, radiation oncology, cancer surgery, immunology, and cancer research. Offers balanced and synthesized content on clinical science, clinical and translational research, and evidence-based practice for cutting-edge immunotherapies.  Discusses clinical applications of immunotherapies in common types of cancer including melanoma, breast cancer, pancreatic cancer, colon and rectum cancer, prostate cancer, leukemias, and hematologic malignancies.  Includes dedicated chapters on immune responses, innate immunity, active immunization against cancer, and cell-based therapies by leading experts.  Covers key topics such as cancer immunotherapy in the presence of COVID-19, immunotherapeutics, new findings concerning the role of the microbiome in immunotherapy, advances in engineered cell-based therapies, and active immunization against cancer.  An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud.  See more
Current price €120.64
Original price €126.99
Save 5%
A01=John E. NiederhuberAge Group_UncategorizedAuthor_John E. Niederhuberautomatic-updateCategory1=Non-FictionCategory=MJCLCOP=United StatesDelivery_Delivery within 10-20 working daysLanguage_EnglishPA=In stockPrice_€100 and abovePS=Activesoftlaunch
Delivery/Collection within 10-20 working days
Product Details
  • Weight: 550g
  • Dimensions: 152 x 229mm
  • Publication Date: 09 Jun 2023
  • Publisher: Elsevier - Health Sciences Division
  • Publication City/Country: United States
  • Language: English
  • ISBN13: 9780323877633

About John E. Niederhuber

Dr John Niederhuber is formerly Executive Vice President of the Inova Health System; President and CEO of the Genomics and Bioinformatics Research Institute in Fairfax Virginia; Professor in the Department of Public Health Sciences at the University of Virginia School of Medicine in Charlottesville Virginia; and Deputy Director of The Johns Hopkins Clinical Research Network in Baltimore Maryland. He recently retired from these positions and remains Adjunct Professor of Oncology and Surgery at Johns Hopkins University and is also currently the lead editor of Abeloff's Clinical Oncology 6th edition (2019). Dr Niederhuber is highly well connected and respected in the medical oncology and surgical oncology fields.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept